An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity

Experimental Neurology

Volumn 231, Issue 1, 2011, Pages 160-170

  Patel, Aditiben ^a   Toia, Giuseppe V ^a   Colletta, Kalea ^a   Bradaric, Brinda Desai ^a   Carvey, Paul M ^a   Hendey, Bill ^a  

^a RUSH UNIVERSITY   (United States)

Author keywords

Angiogenesis; Blood brain barrier; Disease progression; Microglia; Neuroinflammation; Parkinson's disease; ZO 1

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTYLPHENYLALANYLVALINE; CYCLOPEPTIDE; NEUROPROTECTIVE AGENT; OCCLUDIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CELL COUNT; CELL LOSS; CELL STRUCTURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE MARKER; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TIGHT JUNCTION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PEPTIDES, CYCLIC; SUBSTANTIA NIGRA;

EID: 79961028248     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.06.004     Document Type: Article

References (81)

1. Akiyama H., Kawamata T., Dedhar S., McGeer P.L. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J. Neuroimmunol. 1991, 32:19-28.
2. Antonini A., Moresco R.M., Gobbo C., De Notaris R., Panzacchi A., Barone P., Bonifati V., Pezzoli G., Fazio F. Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2). Neurol. Sci. 2002, 23(Suppl. 2):S51-S52.
3. Astradsson A., Jenkins B.G., Choi J.K., Hallett P.J., Levesque M.A., McDowell J.S., Brownell A.L., Spealman R.D., Isacson O. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates-evidence from in vivo neuroimaging studies. Neurobiol. Dis. 2009, 35:348-351.
4. Aumailley M., Gurrath M., Muller G., Calvete J., Timpl R., Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991, 291:50-54.
5. Baluk P., Lee C.G., Link H., Ator E., Haskell A., Elias J.A., McDonald D.M. Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am. J. Pathol. 2004, 165:1071-1085.
6. Barcia C., Bautista V., Sanchez-Bahillo A., Fernandez-Villalba E., Faucheux B., Poza y Poza M., Fernandez Barreiro A., Hirsch E.C., Herrero M.T. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J. Neural Transm. 2005, 112:1237-1248.
7. Barcia C., Emborg M.E., Hirsch E.C., Herrero M.T. Blood vessels and parkinsonism. Front. Biosci. 2004, 9:277-282.
8. Beauchesne E., Desjardins P., Hazell A.S., Butterworth R.F. Altered expression of tight junction proteins and matrix metalloproteinases in thiamine-deficient mouse brain. Neurochem. Int. 2009, 55:275-281.
9. Bennett J., Basivireddy J., Kollar A., Biron K.E., Reickmann P., Jefferies W.A., McQuaid S. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J. Neuroimmunol. 2010, 229:180-191.
10. Bowenkamp K.E., David D., Lapchak P.L., Henry M.A., Granholm A.C., Hoffer B.J., Mahalik T.J. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp. Brain Res. 1996, 111:1-7.
11. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.M., Duyckaerts C., Flavell R.A., Hirsch E.C., Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin Invest. 2009, 119:182-192.
12. Brooks P.C. Role of integrins in angiogenesis. Eur. J. Cancer 1996, 32A:2423-2429.
13. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
14. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
15. Brown L.F., Detmar M., Claffey K., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
16. Carvey P.M., Hendey B., Monahan A.J. The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J. Neurochem. 2009, 111:291-314.
17. Carvey P.M., Zhao C.H., Hendey B., Lum H., Trachtenberg J., Desai B.S., Snyder J., Zhu Y.G., Ling Z.D. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur. J. Neurosci. 2005, 22:1158-1168.
18. Caudle W.M., Zhang J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp. Neurol. 2009, 220:230-233.
19. Chavakis E., Riecke B., Lin J., Linn T., Bretzel R.G., Preissner K.T., Brownlee M., Hammes H.P. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia 2002, 45:262-267.
20. Chen X., Lan X., Roche I., Liu R., Geiger J.D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J. Neurochem. 2008, 107:1147-1157.
21. Chung Y.C., Kim S.R., Jin B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J. Immunol. 2010, 185:1230-1237.
22. Chung Y.C., Ko H.W., Bok E., Park E.S., Huh S.H., Nam J.H., Jin B.K. The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 2010, 43:225-232.
23. Claes A., Wesseling P., Jeuken J., Maass C., Heerschap A., Leenders W.P. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol. Cancer Ther. 2008, 7:71-78.
24. Cuervo A.M., Wong E.S., Martinez-Vicente M. Protein degradation, aggregation, and misfolding. Mov. Disord. 2010, 25(Suppl. 1):S49-S54.
25. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
26. Desai B.S., Schneider J.A., Li J.L., Carvey P.M., Hendey B. Evidence of angiogenic vessels in Alzheimer's disease. J. Neural Transm. 2009, 116:587-597.
27. Ding M., Robinson J.M., Behrens B.C., Vandre D.D. The microtubule cytoskeleton in human phagocytic leukocytes is a highly dynamic structure. Eur. J. Cell Biol. 1995, 66:234-245.
28. Eddy R.J., Pierini L.M., Maxfield F.R. Microtubule asymmetry during neutrophil polarization and migration. Mol. Biol. Cell 2002, 13:4470-4483.
29. Fato R., Bergamini C., Leoni S., Strocchi P., Lenaz G. Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem. Res. 2008, 33:2487-2501.
30. Faucheux B.A., Bonnet A.M., Agid Y., Hirsch E.C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999, 353:981-982.
31. Fernstrom J.D., Fernstrom M.H. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J. Nutr. 2007, 137:1539S-1547S. discussion 1548S.
32. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., Cheresh D.A. Definition of two angiogenic pathways by distinct alpha V integrins. Science 1995, 270:1500-1502.
33. Ginsberg M.H., Partridge A., Shattil S.J. Integrin regulation. Curr. Opin. Cell Biol. 2005, 17:509-516.
34. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161.
35. Holley J.E., Newcombe J., Whatmore J.L., Gutowski N.J. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci. Lett. 2010, 470:65-70.
36. Horton M. Vitronectin receptor: tissue specific expression or adaptation to culture?. Int. J. Exp. Pathol. 1990, 71:741-759.
37. Hynes R.O., Zhao Q. The evolution of cell adhesion. J. Cell Biol. 2000, 150:F89-F96.
38. Ito D., Tanaka K., Suzuki S., Dembo T., Fukuuchi Y. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 2001, 32:1208-1215.
39. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9:685-693.
40. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
41. Kawaguchi M., Hosotani R., Ohishi S., Fujii N., Tulachan S.S., Koizumi M., Toyoda E., Masui T., Nakajima S., Tsuji S., Ida J., Fujimoto K., Wada M., Doi R., Imamura M. A novel synthetic Arg-Gly-Asp-containing peptide cyclo(?RGDf==V-) is the potent inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 2001, 288:711-717.
42. Kenneth N.S., Rocha S. Regulation of gene expression by hypoxia. Biochem. J. 2008, 414:19-29.
43. Kirk S., Frank J.A., Karlik S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?. J. Neurol. Sci. 2004, 217:125-130.
44. Kniesel U., Wolburg H. Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 2000, 20:57-76.
45. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19:312-318.
46. Lee J.K., Tran T., Tansey M.G. Neuroinflammation in Parkinson's disease. J. Neuroimmune Pharmacol. 2009, 4:419-429.
47. Li W., Prakash R., Kelly-Cobbs A.I., Ogbi S., Kozak A., El-Remessy A.B., Schreihofer D.A., Fagan S.C., Ergul A. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes 2010, 59:228-235.
48. Lyden A., Bondesson U., Larsson B.S., Lindquist N.G., Olsson L.I. Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues. Acta Pharmacol. Toxicol. (Copenh) 1985, 57:130-135.
49. Marti H.H. Angiogenesis-a self-adapting principle in hypoxia. EXS 2005, 163-180.
50. Maubant S., Saint-Dizier D., Boutillon M., Perron-Sierra F., Casara P.J., Hickman J.A., Tucker G.C., Van Obberghen-Schilling E. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 2006, 108:3035-3044.
51. Milner R. Microglial expression of alphavbeta3 and alphavbeta5 integrins is regulated by cytokines and the extracellular matrix: beta5 integrin null microglia show no defects in adhesion or MMP-9 expression on vitronectin. Glia 2009, 57:714-723.
52. Milner R., Campbell I.L. The extracellular matrix and cytokines regulate microglial integrin expression and activation. J. Immunol. 2003, 170:3850-3858.
53. Milner R., Frost E., Nishimura S., Delcommenne M., Streuli C., Pytela R., Ffrench-Constant C. Expression of alpha vbeta3 and alpha vbeta8 integrins during oligodendrocyte precursor differentiation in the presence and absence of axons. Glia 1997, 21:350-360.
54. Nagy J.A., Benjamin L., Zeng H., Dvorak A.M., Dvorak H.F. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008, 11:109-119.
55. Nwanze E., Souverbie F., Jonsson G., Sundstrom E. Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity. Neurotoxicology 1995, 16:469-477.
56. Pearce R.K., Owen A., Daniel S., Jenner P., Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 1997, 104:661-677.
57. Petrov T., Howarth A.G., Krukoff T.L., Stevenson B.R. Distribution of the tight junction-associated protein ZO-1 in circumventricular organs of the CNS. Brain Res. Mol. Brain Res. 1994, 21:235-246.
58. Pinkstaff J.K., Detterich J., Lynch G., Gall C. Integrin subunit gene expression is regionally differentiated in adult brain. J. Neurosci. 1999, 19:1541-1556.
59. Pogue A.I., Lukiw W.J. Angiogenic signaling in Alzheimer's disease. NeuroReport 2004, 15:1507-1510.
60. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 2001, 76:1265-1274.
61. Roscoe W.A., Welsh M.E., Carter D.E., Karlik S.J. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. J. Neuroimmunol. 2009, 209:6-15.
62. Ruoslahti E., Pierschbacher M.D. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986, 44:517-518.
63. Schultheiss C., Blechert B., Gaertner F.C., Drecoll E., Mueller J., Weber G.F., Drzezga A., Essler M. In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease. Angiogenesis 2006, 9:59-65.
64. Sethi G., Sung B., Aggarwal B.B. TNF: a master switch for inflammation to cancer. Front. Biosci. 2008, 13:5094-5107.
65. Shimamura N., Matchett G., Solaroglu I., Tsubokawa T., Ohkuma H., Zhang J. Inhibition of integrin alphavbeta3 reduces blood-brain barrier breakdown in focal ischemia in rats. J. Neurosci. Res. 2006, 84:1837-1847.
66. Somanath P.R., Malinin N.L., Byzova T.V. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12:177-185.
67. Speciale S.G., Liang C.L., Sonsalla P.K., Edwards R.H., German D.C. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 1998, 84:1177-1185.
68. Szekanecz Z., Besenyei T., Paragh G., Koch A.E. Angiogenesis in rheumatoid arthritis. Autoimmunity 2009, 42:563-573.
69. Thirumangalakudi L., Samany P.G., Owoso A., Wiskar B., Grammas P. Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J. Alzheimers Dis. 2006, 10:111-118.
70. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64:3731-3736.
71. Turmel H., Hartmann A., Parain K., Douhou A., Srinivasan A., Agid Y., Hirsch E.C. Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Mov. Disord. 2001, 16:185-189.
72. Vagnucci A.H., Li W.W. Alzheimer's disease and angiogenesis. Lancet 2003, 361:605-608.
73. Voronov E., Carmi Y., Apte R.N. Role of IL-1-mediated inflammation in tumor angiogenesis. Adv. Exp. Med. Biol. 2007, 601:265-270.
74. Wada K., Arai H., Takanashi M., Fukae J., Oizumi H., Yasuda T., Mizuno Y., Mochizuki H. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. NeuroReport 2006, 17:705-709.
75. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., Munn L.L., Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004, 6:553-563.
76. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc. Pharmacol. 2002, 38:323-337.
77. Yasuda T., Fukuda-Tani M., Nihira T., Wada K., Hattori N., Mizuno Y., Mochizuki H. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease. Exp. Neurol. 2007, 206:308-317.
78. Zand L., Ryu J.K., McLarnon J.G. Induction of angiogenesis in the beta-amyloid peptide-injected rat hippocampus. NeuroReport 2005, 16:129-132.
79. Zhang M.Y., Kagan N., Sung M.L., Zaleska M.M., Monaghan M. Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2008, 874:51-56.
80. Zhao C., Ling Z., Newman M.B., Bhatia A., Carvey P.M. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol. Dis. 2007, 26:36-46.
81. Zhu J., Chu C.T. Mitochondrial dysfunction in Parkinson's disease. J. Alzheimers Dis. 2010, 20(Suppl. 2):S325-S334.